Cellromax Science Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Revenue	20,976	22,184	21,630
Other Revenue	-	-	-0
Revenue	20,976	22,184	21,630
Revenue Growth (YoY)	-6.17%	2.56%	-
Cost of Revenue	10,841	11,637	9,346
Gross Profit	10,135	10,547	12,284
Selling, General & Admin	7,191	7,100	6,228
Amortization of Goodwill & Intangibles	7.27	4.02	1.67
Other Operating Expenses	137.96	133.87	112.08
Operating Expenses	7,805	7,712	6,784
Operating Income	2,330	2,835	5,501
Interest Expense	-38.21	-50.49	-37.78
Interest & Investment Income	679.9	780.22	1,376
Currency Exchange Gain (Loss)	-2.23	-4.8	-2.83
Other Non Operating Income (Expenses)	65.13	-247.81	-1,783
EBT Excluding Unusual Items	3,035	3,313	5,052
Gain (Loss) on Sale of Investments	117.13	127.93	71.81
Gain (Loss) on Sale of Assets	10.82	10.82	11.85
Pretax Income	3,163	3,451	5,136
Income Tax Expense	-255.45	484.82	1,319
Net Income	3,418	2,966	3,817
Net Income to Common	3,418	2,966	3,817
Net Income Growth	45.40%	-22.29%	-
Shares Outstanding (Basic)	11	11	10
Shares Outstanding (Diluted)	11	11	10
Shares Change (YoY)	6.03%	9.70%	-
EPS (Basic)	304.63	264.20	367.00
EPS (Diluted)	301.97	261.00	367.00
EPS Growth	37.54%	-28.88%	-
Free Cash Flow	2,052	1,707	6,088
Free Cash Flow Per Share	180.64	149.58	585.32
Gross Margin	48.32%	47.54%	56.79%
Operating Margin	11.11%	12.78%	25.43%
Profit Margin	16.30%	13.37%	17.65%
Free Cash Flow Margin	9.78%	7.69%	28.15%
EBITDA	2,807	3,314	5,936
EBITDA Margin	13.38%	14.94%	27.44%
D&A For EBITDA	476.9	478.45	435.41
EBIT	2,330	2,835	5,501
EBIT Margin	11.11%	12.78%	25.43%
Effective Tax Rate	-	14.05%	25.68%
Advertising Expenses	-	639.1	484.04